ABSTRACT
About Erythropoietin Drugs
The global erythropoietin drugs market is expected to witness a slow growth rate during the forecast period. In 2016, EMEA dominated the market, followed by the Americas and APAC. India and China are the leading countries in the market in APAC. While Sandoz and Dr. Reddy's Laboratories dominate the erythropoietin (EPO) drugs market in India, the market in China is led by 3SBio and Beijing SL Pharmaceutical. EMEA is also witnessing positive growth, mainly due to an increase in the manufacture of EPO biosimilars by European vendors and the use of biosimilar products in this region. However, the situation in the US is complicated due to the formation of a new legislative body to govern biosimilar products.
Technavio’s analysts forecast the global erythropoietin drugs market to grow at a CAGR of 0.79% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global erythropoietin drugs market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of branded and biosimilars used for the treatment of anemia due to renal diseases, cancer chemotherapy, antiretroviral therapy, and wounds and neural diseases.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Erythropoietin Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• Amgen
• Hoffmann-LA Roche
• Johnson & Johnson
• Kyowa Hakko Kirin
Other prominent vendors
• Ahua Pharmaceutical
• 3SBio
• BIOSIDUS
• Biocon
• Boehringer Ingelheim
• Chugai Pharmaceutical
• Celltrion
• Intas Pharmaceuticals
• Cipla
• DAICHI SANKYO
• Dr. Reddy's Laboratories
• Teva Pharmaceutical Industries
• Dragon Pharma
• Huaxin High Biotechnology
• JCR Pharmaceuticals
• Shanghai Kehua Bio-Engineering
• LG Life Science
• Novartis
• Pfizer
• Sandoz International
• Shenyang Sunshine Pharmaceutical
• Shenzhen Sai Bao Er Bio-Pharmaceutical
• Sihuan Pharmaceutical
• STADA
• Uni-Bio Science
• Wanbang Biochemical Pharmaceuticals
Market driver
• Increase in chronic kidney disease (CKD) and dialysis patient pool.
• For a full, detailed list, view our report
Market challenge
• Physicians' reluctance to prescribe biosimilars.
• For a full, detailed list, view our report
Market trend
• Advent of biosimilars expected to improve the treatment rates.
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
• Market overview
• Top-vendor offerings
PART 03: Market research methodology
• Research methodology
• Economic indicators
PART 04: Introduction
• Key market highlights
PART 05: Biosimilars: Overview
• Comparative analysis of biosimilars and generics
• Biosimilars market opportunities
• Challenges for new entrants
PART 06: Erythropoietin: An overview
• Clinical uses of EPO
• Abusive uses of EPO
• Risks of EPO use
PART 07: Market landscape
• Market overview
• Five forces analysis
PART 08: Pipeline portfolio
• Phase III pipeline portfolio
• Phase II pipeline portfolio
• Phase I pipeline portfolio
• Pre-clinical pipeline portfolio
PART 09: Marketed products portfolio
PART 10: Market segmentation by end-user
• Hospitals
• Retail pharmacies
PART 11: Market segmentation by application
• End-stage renal disease
• Cancer
• HIV
• Wounds and neural disease
PART 12: Market segmentation by product
• First-generation erythropoietin formulation
• Second-generation erythropoietin formulation
• Biosimilars
PART 13: Geographical segmentation
• Erythropoietin drugs market in EMEA
• Erythropoietin drugs market in Europe
• Erythropoietin drugs market in Americas
• Erythropoietin drugs market in US
• Erythropoietin drugs market in APAC
• Erythropoietin drugs market in China
• Erythropoietin drugs market in Japan
• Market overview
PART 14: Market drivers
• Rise in number of patent expiries
• Need for cost-effective treatment
• Increase in CKD and dialysis patient pool
PART 15: Impact of drivers
PART 16: Market challenges
• Physicians' reluctance to prescribe biosimilars
• Multiple manufacturing complexities
• Development of alternative therapies
• Complicated regulatory framework
PART 17: Impact of drivers and challenges
PART 18: Market trends
• Advent of biosimilars expected to improve the treatment rates
• Outsourcing of biosimilar manufacturing activities
• High growth in the emerging markets
PART 19: Vendor landscape
• Competitive scenario
• Other prominent vendors
PART 20: Key vendor analysis
• F. Hoffmann-La Roche
• Amgen
• Johnson & Johnson
• Kyowa Hakko Kirin
PART 21: Appendix
• List of abbreviations
List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Key buying criteria for erythropoietin drugs 2016
Exhibit 03: Impact of key customer segments on the market 2016
Exhibit 04: Definition of biosimilars in different regions
Exhibit 05: Comparison between biosimilars and generics
Exhibit 06: Factors affecting biologics and biosimilars market
Exhibit 07: Impact of biosimilars cost savings on various sectors
Exhibit 08: Factors affecting success of biosimilars
Exhibit 09: Biosimilars industry: Point-of-view
Exhibit 10: Factors influencing uptake of biosimilars
Exhibit 11: Global erythropoietin drugs market: Strategic factors for new biosimilar entrants
Exhibit 12: Challenges for new entrants
Exhibit 13: Historical timeline of EPO development
Exhibit 14: Globally approved EPO biosimilars
Exhibit 15: Overview of global erythropoietin drugs market (2016-2021)
Exhibit 16: Global erythropoietin drugs market 2016-2021 ($ billions)
Exhibit 17: Key strategies in global erythropoietin drugs market
Exhibit 18: Prospects of the global erythropoietin drugs market
Exhibit 19: Global erythropoietin drugs market snapshot: Developed and emerging markets 2016
Exhibit 20: New opportunities in global erythropoietin drugs market
Exhibit 21: Impact of factors affecting the market 2016 and 2021
Exhibit 22: Factors affecting global erythropoietin drugs market
Exhibit 23: Five forces analysis
Exhibit 24: Share of pipeline molecules
Exhibit 25: Pipeline share of biologics and biosimilars in global erythropoietin drugs market 2016
Exhibit 26: Phase III pipeline portfolio
Exhibit 27: Phase II pipeline portfolio
Exhibit 28: Phase I pipeline portfolio
Exhibit 29: Pre-clinical pipeline portfolio
Exhibit 30: Share of biologics and biosimilars in global erythropoietin drugs market 2016
Exhibit 31: Synopsis of marketed products
Exhibit 32: Biosimilars market segmentation by end-user 2016
Exhibit 33: Global erythropoietin drugs market segmentation in by product type 2016
Exhibit 34: Snapshot of global erythropoietin drugs market by geography
Exhibit 35: Erythropoietin drugs market revenue by geography 2016-2021 ($ billions)
Exhibit 36: Overview of erythropoietin drugs market in EMEA (2016)
Exhibit 37: Erythropoietin drugs market in EMEA 2016-2021 ($ billions)
Exhibit 38: Share of erythropoietin drugs market in Europe 2016
Exhibit 39: Erythropoietin drugs market in Europe 2016-2021 ($ billions)
Exhibit 40: Europe erythropoietin drugs market: Opportunity analysis
Exhibit 41: Analysis of erythropoietin biosimilar marketed products in Europe
Exhibit 42: PEST analysis: Erythropoietin drugs market in Europe 2016
Exhibit 43: Overview of erythropoietin drugs market in Americas (2016)
Exhibit 44: Erythropoietin drugs market in Americas 2016-2021 ($ billions)
Exhibit 45: Erythropoietin drugs market in US 2016-2021 ($ billions)
Exhibit 46: Erythropoietin drugs market in US: Opportunity analysis
Exhibit 47: PEST analysis: Erythropoietin drugs market in US
Exhibit 48: Overview of erythropoietin drugs market in APAC (2016)
Exhibit 49: Erythropoietin drugs market in APAC 2016-2021 ($ billions)
Exhibit 50: Market share of erythropoietin drugs in APAC
Exhibit 51: Erythropoietin drugs market in China 2016-2021 ($ millions)
Exhibit 52: China erythropoietin drugs market: Opportunity analysis
Exhibit 53: PEST analysis: Erythropoietin drugs market in China
Exhibit 54: Erythropoietin drugs market in Japan 2016-2021 ($ millions)
Exhibit 55: Erythropoietin drugs market in Japan 2016: Opportunity analysis
Exhibit 56: PEST analysis: Erythropoietin drugs market in Japan 2016
Exhibit 57: Impact of drivers and challenges in global erythropoietin drugs market
Exhibit 58: Patent analysis of biologicals in the US
Exhibit 59: Patent analysis of biologicals in Europe
Exhibit 60: Impact of drivers
Exhibit 61: Key reasons why physicians are reluctant to prescribe biosimilar drugs
Exhibit 62: Approval process of biologicals versus biosimilars via Public Health Service Act (PHSA) in US
Exhibit 63: Impact of drivers and challenges
Exhibit 64: Impact of trends in global erythropoietin drugs market
Exhibit 65: Few biosimilars currently under pipeline
Exhibit 66: Competitive structure analysis of global erythropoietin drugs market 2016
Exhibit 67: Geographical presence of key vendors
Exhibit 68: Competitive scenario: Global erythropoietin drugs market vendors 2016-2021
Exhibit 69: F. Hoffmann La-Roche: Key highlights
Exhibit 70: F. Hoffmann La-Roche: Strength assessment
Exhibit 71: F. Hoffmann La-Roche: Strategy assessment
Exhibit 72: F. Hoffmann La-Roche: Opportunity assessment
Exhibit 73: Amgen: Key highlights
Exhibit 74: Amgen: Strength assessment
Exhibit 75: Amgen: Strategy assessment
Exhibit 76: Amgen: Opportunity assessment
Exhibit 77: Johnson & Johnson: Profile
Exhibit 78: Johnson & Johnson: Strength assessment
Exhibit 79: Johnson & Johnson: Strategy assessment
Exhibit 80: Johnson & Johnson: Opportunity assessment
Exhibit 81: Kyowa Hakko Kirin: Highlights
Exhibit 82: Kyowa Hakko Kirin: Strength assessment
Exhibit 83: Kyowa Hakko Kirin: Strategy assessment
Exhibit 84: Kyowa Hakko Kirin: Opportunity assessment
